Molecular events in the pathogenesis of vulvar squamous cell carcinoma
- PMID: 33032902
- PMCID: PMC7749059
- DOI: 10.1053/j.semdp.2020.09.010
Molecular events in the pathogenesis of vulvar squamous cell carcinoma
Abstract
Vulvar squamous cell carcinomas (VSCC), which constitute over 90% of vulvar malignancies in adults, are classifiable into 2 subgroups that are mostly clinicopathologically distinct, a classification that is fundamentally based whether or not the tumors are HPV-mediated. In this review, we aim to summarize the recent advances in the understanding of molecular events in the pathogenesis of VSCC, including common and targetable mutations, copy number alterations, epigenetics, noncoding RNAs, and tumor immune microenvironment, which may provide insight into the future management of the disease. These events show substantial differences between the 2 subgroups, although significant areas of overlap exist. Recurrent, driver mutations appear to be substantially more prevalent in HPV(-) VSCC. TP53 mutations are the most common somatic mutations in VSCC overall, and are notably predominant in the HPV(-) VSCC, where 30-88% show a mutation. TP53 mutations are associated with worse patient outcomes, and co-mutations between TP53 and either HRAS, PIK3CA or CDKN2A appear to define subsets with even worse outcomes. A wide variety of other somatic mutations have been identified, including a subset with different mutational frequencies between HPV(+) and HPV(-) VSCC. CDKN2A mutations are common, and have been identified in 21 to 55% of HPV(-) VSCC, and in 2 to 25% of HPV(+) VSCC. Hypermethylation of CDKN2A is the most frequently reported epigenetic alteration in VSCC and the expression of some microRNAs may be associated with patient outcomes. The PTEN/PI3K/AKT/mTOR pathway is commonly altered in HPV(+) VSCC, and is accordingly potentially targetable. HPV-positivity/p16 block expression by immunohistochemistry has been found to be an independent prognostic marker for improved survival in VSCC, and may have some predictive value in VSCC patients treated with definitive radiotherapy. 22-39.3% and 68% of VSCC show EGFR amplification and protein overexpression respectively, although the prognostic and predictive value of an EGFR alteration requires additional study. Recurrent chromosomal gains in VSCCs have been found at 1q, 2q, 3q, 4p, 5p, 7p, 8p, 8q, and 12q, and there may be differential patterns of alterations depending on HPV-status. At least one-third of VSCC patients may potentially benefit from immune checkpoint inhibition therapy, based on a high frequency of PD-L1 expression or amplification, or a high tumor mutational burden. Additional studies are ultimately required to better understand the global landscape of genetic and epigenetic alterations in VSCC, and to identify and test potential targets for clinical application.
Keywords: CDKN2A, Differentiated vulvar intraepithelial neoplasia (dVIN); High-grade squamous intraepithelial lesions (HSIL), Molecular events, Mutation, PI3K/AKT/mTOR, TP53, Vulvar squamous cell carcinoma (VSCC).
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7749059/bin/nihms-1636704-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7749059/bin/nihms-1636704-f0002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7749059/bin/nihms-1636704-f0003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7749059/bin/nihms-1636704-f0004.gif)
![Figure 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7749059/bin/nihms-1636704-f0005.gif)
![Figure 6.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7749059/bin/nihms-1636704-f0006.gif)
Similar articles
-
Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome.Mod Pathol. 2021 Feb;34(2):508-518. doi: 10.1038/s41379-020-00651-3. Epub 2020 Aug 13. Mod Pathol. 2021. PMID: 32792599
-
Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.Gynecol Oncol. 2018 Sep;150(3):552-561. doi: 10.1016/j.ygyno.2018.06.026. Epub 2018 Jul 3. Gynecol Oncol. 2018. PMID: 29980281
-
Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach.Mod Pathol. 2023 Jun;36(6):100145. doi: 10.1016/j.modpat.2023.100145. Epub 2023 Feb 22. Mod Pathol. 2023. PMID: 36828360
-
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy.Ann Oncol. 2016 Sep;27(9):1696-705. doi: 10.1093/annonc/mdw242. Epub 2016 Jun 20. Ann Oncol. 2016. PMID: 27329249 Review.
-
Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature.Gynecol Oncol. 2015 Jan;136(1):143-57. doi: 10.1016/j.ygyno.2014.11.002. Epub 2014 Nov 14. Gynecol Oncol. 2015. PMID: 25448458 Review.
Cited by
-
Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.Mol Biomed. 2024 Apr 15;5(1):13. doi: 10.1186/s43556-024-00176-0. Mol Biomed. 2024. PMID: 38616230 Free PMC article. Review.
-
Snail Immunoexpression in Endometrioid Endometrial Carcinomas.Curr Health Sci J. 2022 Oct-Dec;48(4):393-397. doi: 10.12865/CHSJ.48.04.05. Epub 2022 Dec 31. Curr Health Sci J. 2022. PMID: 37304794 Free PMC article.
-
The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer.Cancers (Basel). 2023 Feb 7;15(4):1046. doi: 10.3390/cancers15041046. Cancers (Basel). 2023. PMID: 36831389 Free PMC article.
-
Vulvar Cancer: 2021 Revised FIGO Staging System and the Role of Imaging.Cancers (Basel). 2022 Apr 30;14(9):2264. doi: 10.3390/cancers14092264. Cancers (Basel). 2022. PMID: 35565394 Free PMC article. Review.
-
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?Cancers (Basel). 2021 Aug 12;13(16):4061. doi: 10.3390/cancers13164061. Cancers (Basel). 2021. PMID: 34439215 Free PMC article. Review.
References
-
- Siegel RL, Miller KD, and Jemal A, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7–30. - PubMed
-
- Kurman RJ, et al., WHO Classification of Tumors of Female Reproductive Organs. Lyon: IARC; 2014.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous